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In human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are well established in
pancreatic ductal adenocarcinoma (PDAC). Although loss of functional p53 pathway and loss of Ink4a/Arf in human
pancreatic acinar cell carcinoma (PACC) and pancreatic neuroendocrine tumor (PanNET) are identified, their direct
roles in tumorigenesis of PACC and PanNET remain to be determined. Using transgenic mouse models expressing
the viral oncogene polyoma middle T antigen (PyMT), we demonstrate that p53 loss in pancreatic Pdx1+
progenitor cells results in aggressive PACC, whereas Ink4a/Arf loss results in PanNETs. Concurrent loss of p53 and
Ink4a/Arf resembles loss of p53 alone, suggesting that Ink4a/Arf loss has no additive effect to PACC progression.
Our results show that specific tumor suppressor genotypes provocatively influence the tumor biological
phenotypes in pancreatic progenitor cells. Additionally, in a mouse model of β-cell hyperplasia, we demonstrate
that p53 and Ink4a/Arf play cooperative roles in constraining the progression of PanNETs.
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Pancreatic acinar cell carcinomas (PACCs) and pancreatic neuroen-
docrine tumors (PanNETs) are neoplasms that each account for 1%
to 2% of pancreatic cancers in adults [1,2]. PACC has a 25% to 50%
5-year survival rate, whereas PanNET survival is 100% for low-stage
cancers and drops to 55% for stage IV cancers [2–4]. Both PACCs
and PanNETs have a tremendous amount of genomic instability at
the nucleotide and chromosomal level [2,5–7]. Complicating clinical
diagnosis, PACC can also present as mixed acinar-neuroendocrine
carcinomas (neuroendocrine differentiation in N30% of tumor),
mixed acinar-ductal carcinomas, or mixed with both neuroendocrine
and ductal components [8]. Because of the availability of clinical
PanNET and PACC specimens, studies have been limited, and the
pathogenesis of both cancers is poorly understood.
Alterations in PDAC are well-defined and commonly include
activating mutations in KRAS as the driver mutations and alterations
in the tumor suppressors p53 (50%-70% of cases) and p16Ink4a
(80%-95% of cases) [9]. The loss of p53 and p16Ink4a in PDAC
suggests important, nonredundant roles in tumorigenesis. The
anticancer functions of p53 include activating DNA repair enzymes,
stopping the G1 to S phase transition by inducing p21 expression,
and initiating apoptosis [6]. The Ink4a/Arf (CDKN2A) locus encodes
tumor suppressors, p16Ink4a and p14Arf (p19Arf in mouse). p16Ink4ais a cyclin-dependent kinase inhibitor that binds to CDK4/6 to
prevent interaction with cyclin D, effectively stopping the G1 to S
phase transition [10]. Arf stabilizes p53 by promoting MDM2
degradation [11,12]. In addition, Arf possesses p53-independent
functions such as cell cycle arrest, apoptosis, angiogenesis, and
ribosomal RNA processing [13–17]. It has also been shown that Arf
inhibits tumor cell colonization independent of p53 in a mouse
model of PDAC metastasis [18].
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sequencing analysis [19,20], whereas p53 loss of heterozygosity was
observed in 50% and 70% of PACCs [20,21]. Because of advances in
sequencing technology, recent studies report that p53 loss by mutation
and chromosomal loss is common in PACC [4,22–24]. Comprehensive
genomic studies found that 13% to 23% of primary tumors had TP53
point mutations or truncations [4,22] and 39% to 53% of primary
tumors had TP53 loss of heterozygosity [22,23]. In metastatic tumors,
point mutations were identified in 31% and chromosomal deletions in
50%, suggesting that intact p53 is a barrier to metastatic potential [23].
Emphasizing the clinical significance of p53 status in PACC, copy
number alterations and mutation with loss of heterozygosity were
associated with shorter patient survival [23,24]. Although p53 mutations
are rare in panNETs (b3%) [20], the p53 pathway is altered in
approximately 70% of panNETs through aberrant activation of its
negative regulators, including MDM2, MDM4, and WIP1 [6].
Loss of p16Ink4a in PACC occurs in lower frequency than loss of p53.
Genomewide analyses identified homozygous deletion of p16Ink4a in 14%
to 17%of PACCs [4,22]. In PanNETs,p16Ink4a is recognized as commonly
altered and of prognostic value [10,25–27]. For PanNETs, Muscarella and
colleagues analyzed 5 primary tumors and 5metastatic PanNETs for genetic
alteration of p16Ink4a and found that 9 of these 10 tumor specimens contain
inactivating alteration of p16Ink4a [26]. With regard to clinical significance,
low p16Ink4a levels in tumor tissue and promoter hypermethylation are
negative prognostic factors of poor survival [10,27].
Although mouse model studies demonstrated that alterations in p53
and p16/p19 enable the malignant progression of PDAC [9,18,28], their
contributions to PACC and PanNET are still not determined. To address
the roles of p53 and p16/p19 in PACC and PanNET progression, we
used mouse models that produce PACC and β-cell hyperplasia [29]. We
previously showed that PyMT induction in Pdx1+ pancreatic progenitor
cells results in β-cell hyperplasia in the majority of the mice and lethal
PACC in b10% of mice, whereas PyMT induction in β cells results only
in β-cell hyperplasia [29]. Although PyMT is not implicated in human
cancer, it remains an important experimental tool because it stimulates
signaling pathways important in human cancers: the mitogen-activated
protein kinase, the phosphatidylinositol 3-kinase cascades, and theHippo
pathway [30–32]. Although the driver mutations for PACC and
PanNET are unknown, activation of the mitogen-activated protein
kinase pathway and phosphatidylinositol 3-kinase pathway is found in
PACC and PanNET [4,33,34]. In this present study, we investigated the
contribution of separate and combined p53 and p16/p19 loss to PACC
and PanNET tumorigenesis in the mouse models. We find that in the
context of PyMT expression in pancreatic Pdx1+ progenitor cells, p53
loss results in highly malignant PACC, whereas p16/p19 loss results in
nonmetastatic PanNETs. However, concurrent loss of p53 and p16/p19
resembles loss of p53, suggesting that p16/p19 loss has no additive effect
to PACC progression promoted by loss of p53 alone. In the context of
PyMT expression in pancreatic β cells, p53 loss results in nonmetastatic
PanNETs, whereas p16/p19 loss results in metastatic PanNETs.
Concurrent loss of p53 and p16/p19 in pancreatic β-cells increases
PanNET incidence compared with loss of either tumor suppressor alone.
Materials and Methods
Mouse Strains, Animal Husbandry, and Genotyping
Mice used in this study have a mixed genetic background.
Pdx1-tTA knock-in mice were on an ICR genetic background [35].
tet-o-PyMT-IRES-Luc mice were generated on C57BL/6 geneticbackground [29] and were crossed to p48-cre; p53lox/lox and p48-cre;
p16/p19lox/lox mice on an FVB/N background [36,37]. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. All mice were housed in accordance with
institutional guidelines. Doxycycline rodent diets were obtained from
Harlan-Teklad (Madison, WI). All procedures involving mice were
approved by the Institutional Animal Care and Use Committee.
Genotypes were determined by polymerase chain reaction using
mouse ear DNA kept at −20°C or tumor DNA kept at −80°C,
prepared through lysis in 0.05 MNaOH with 98°C incubation for 20
minutes and addition of 10 mM Tris–0.2 mM EDTA (pH 7.4). Cre
recombinase excision of p53 and p16/p19 in tumor tissues was
verified using primers for the recombined alleles.
Polymerase chain reaction primers were as follows: for PyMT: 5′-CTG
CTACTGCACCCAGACAA-3′ and 5′-TCCGCCGTTTTGGATTA
TAC-3′ (a 468-bp product); for tTA: 5′-GGACGAGCTCCACTTA
GACG-3′ and 5′-AGGGCATCGGTAAACATCTG-3′ (a 200-bp
product); for rtTA: 5′-GTGAAGTGGGTCCGCGTACAG-3′ and
5′-GTACTCGTCAATTCCAAGGGCATCG-3′(a 400-bp product);
for unrecombined p16/p19 allele: 5′-CCTGACTATGGTAG
TAAAGTGG-3′ and 5′-ACGTGTATGCCACCCTGACC-3′ (a
380-bp lox/lox, 280-bp WT product); for recombined p16/p19 allele:
5′-TTGGGAGGCACACTTTCTTGG-3′ (a 280-bp product); for
unrecombined p53 allele: 5′-CACAAAAACAGGTTAAACCCAG-3′
and 5′-AGCACATAGGAGGCAGAGAC-3′ (a 370-bp lox/lox, 240-bp
WT product); for recombined p53 allele: 5′-GAAGACAGAAAAGGG
GAGGG-3′ (a 612-bp product); for p48-cre: 5′-GCGGTCTGGCAG
TAAAAACTATC-3′ and 5′-GTGAAACAGCATTGCTGTCACTT-3′
(a 324-bp product).
Histology and Immunohistochemistry
Mice were sacrificed based on in vivo bioluminescent imaging
(PyMT is linked to a luciferase reporter) when values in the region of
pancreas exceeded 1e6 photons/sec, outward symptoms, and survival
predictions. Mice found dead before sacrifice were dissected, and
when possible, tumor burden, metastasis burden, and histology were
examined. The tumor types were confirmed with immunohisto-
chemistry using antibodies against chymotrypsin to identify acinar
cells, synaptophysin to identify neuroendocrine cells, and keratin 17/
19 to identify ductal cells.
Tissues from dissected mice were fixed in 10% buffered formalin
overnight at room temperature and transferred to 70% ethanol for
long-term storage. Tissues were sectioned into 5-μm slides and
stained for hematoxylin and eosin (H&E) at Histoserv Inc.
(Germantown, MD). Unstained sections were deparrafinized and
rehydrated through a Clear-Rite/ethanol series. Histologic assessment
was confirmed by immunohistochemistry with VECTASTAIN Elite
ABC Kit (Vector Laboratories) performed based on the manufac-
turer's instructions. Primary antibodies used were anti-synaptophysin
(1:100, Vector Labs, VP-S284) as a neuroendocrine marker and anti–
keratin 17/19 (1:300, Cell Signaling, 3984) as a ductal marker. For
automated staining of chymotrypsin, slides were pretreated with
Protease 1 (Ventana) for 16 minutes and primary antibody,
anti-human chymotrypsin antibody (Biodesign International,
1:3000), at 4°C overnight on the Ventana Benchmark platform
according to manufacturer's instructions. The cutoff size used to
differentiate between β-cell hyperplasia and PanNET is 1 mm in
diameter [38].
Figure 1. Analysis of primary tumor specimens from mice with p53 and p16/p19 mutants. Genotyping confirmed Cre-mediated
recombination of the p53lox/lox and p16/p19lox/lox loci in tumor tissues. Genomic DNA from ears is used as control for unrecombined
alleles.
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Survival was evaluated using the Kaplan-Meier method and
statistically checked with the log-rank test using Prism (version 6.0f).
Differences in tumor and metastasis incidence were examined by the
χ2 test. Differences in tumor burden were analyzed by t test. P value
b .05 is considered as statistical significance.
Results
Generation of Mouse Lines
We have previously generated Pdx1-tTA; tet-o-PyMT-IRES-Luc
(inducible PyMT in pancreatic progenitor cells) mouse model and
described that PyMT expression in pancreatic progenitor cells results
in β-cell hyperplasia in the majority of the mice or lethal PACC in
b10% of mice [29]. To delete p53 and p16/p19 in the pancreatic cells
of the PyMT mouse models , we crossed Pdx1-tTA;
tet-o-PyMT-IRES-Luc to p48-cre; p53lox/lox mice and p48-cre; p16/
p19lox/lox mice. The p53 and p16/p19 genomic loci were flanked with
loxP sites [36,37] to allow generate nullizygous gene loci by
Cre-mediated recombination. Cre recombinase was placed under a
p48 promoter, and recombination of p53 and p16/p19 in tumor
tissue was confirmed using primers for the recombined alleles (Figure
1). Expression of Pdx1, a transcription factor necessary for pancreatic
development, occurs at around E8.5 [39]. p48 is expressed slightly
later than Pdx1 and is required to commit cells to a pancreatic fate
[40].
Pdx1-tTA; tet-o-PyMT offers a baseline for comparison to
tumor suppressor loss
Pdx1-tTA; tet-o-PyMT-IRES-Luc; p48-cre mice (n = 100,
Pdx1-tTA; tet-o-MT for short) with mixed genetic background were
used as the control group. Mice were not on doxycycline rodent diet,
allowing PyMT to be induced in cells expressing the Pdx1
transcription factor. The tumor incidence of this genotype was 5%Table 1. Phenotypes of p53 and p16/p19 Loss in PACC and PanNET Mouse Models
Genotype Tumor Incidence (%) P Value
Pdx1-tTA; tet-o-MT; p48-cre p53WT; p16/p19WT 5/100 (5%)
p53lox/lox 4/20 (20%) .020074
p16/p19lox/lox 4/35 (11%) .07102
p53lox/lox; p16/p19lox/lox 4/12 (33%) .000646
RIP7-rtTA; tet-o-MT; p48-cre p53WT; p16/p19WT 0/50 (0%)
p53lox/lox 2/12 (17%) .003341
p16/p19lox/lox 12/60 (20%) .000807
p53lox/lox; p16/p19lox/lox 12/30 (40%) .000002
A, mixed acinar ductal carcinoma; A/N, mixed acinar ductal neuroendocrine carcinoma; U, undeterm(5/100), and tumors were PACC (Table 1), in agreement with the
previously reported tumor characteristics of the PyMT model in pure
C57/BL6 genetic background [29]. Majority of the mice (95%) did
not develop tumors, and only 2 of 100 mice (2%) had liver metastasis
(Table 1). The survival of mice in this genotype, including those found
dead, with or without tumors, is shown in Figure 2A. The phenotype of a
normal pancreas and liver, commonly found in this control group, is
shown in Figure 3A. Representative images of H&E staining of normal
pancreatic tissue, β-cell hyperplasia, and PACC are presented in Figure 4,
A–C, and normal liver histology is presented in Figure 6A.
p53 loss promotes PACC tumorigenesis and shortens survival
Pdx1-tTA; tet-o-PyMT-IRES-Luc; p48-cre; p53lox/lox mice (n = 20,
Pdx1-tTA; tet-o-MT; p53lox/lox for short) have significantly shorter
survival (P = .0002) and higher PACC incidence than Pdx1-tTA;
tet-o-MT mice (20% vs 5%, P = .0025) (Table 1). Figure 3B is a
representative image of a Pdx1-tTA; tet-o-MT; p53lox/lox mixed
acinar-ductal carcinoma with a pancreatic tumor burden of 5463 cm3
and multiple liver metastases. Immunohistochemistry of four tumors
in this genotype revealed three mixed acinar-ductal carcinomas and
one mixed acinar-neuroendocrine carcinoma (Table 1). Figure 5, A–D
displays the immunohistochemical staining of a representative PACC
tumor from the Pdx1-tTA; tet-o-MT; p53lox/lox genotype. The tumor is
mixed with cells of ductal differentiation and no neuroendocrine
components. Separate cells stained positive for ductal and acinar markers,
but importantly, both cell types composed the same tumor, characterizing
it as a mixed acinar-ductal carcinoma. The PACC tumor magnitudes
were extensive (range: 1573-25,480 cm3), and 4 of 4 (100%) mice that
developed PACC had metastasis to the liver (Table 1). The histology of
PACC liver metastasis is shown in Figure 6B. The majority of the tumor
cells in Pdx1-tTA; tet-o-MT; p53lox/lox genotype were positive for
chymotrypsin (an acinar marker) and negative for synaptophysin (a
neuroendocrine marker) (Figure 5, B and C).(χ2) Tumor Incidence PACC PanNET Metastasis (%) P Value Survival
5 pure 0 2/5 (40%)
3A, 1 A/N 0 4/4 (100%) .0002
1 pure 3 0/4 (0%) .0025
2A, 2U 0 4/4 (100%) b.0001
0 0 0 (0%)
0 2 0/2 (0%) .0129
0 12 5/12 (42%) .3951
0 12 4/12 (33%) b.0001
ined because of inability to stain necrotic tissue.
Figure 2. Kaplan-Meier curve displaying contribution of tumor
suppressor loss to survival. (A) The survival of the three experimental
groups with loss of tumor suppressor in pancreatic progenitors
(Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox mice, Pdx1-tTA; tet-o-MT;
p48-cre; p16/p19lox/lox mice, Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox;
p16/p19lox/lox mice) was statistically shorter than the control Pdx1-tTA;
tet-o-MT;p48-cremice.Survival ofPdx1-tTA; tet-o-MT;p48-cre;p53lox/lox;
p16/p19lox/loxwas statistically different from that ofPdx1-tTA; tet-o-MT;
p48-cre; p16/p19lox/lox (P = .0449) but not statistically different from
that of Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox. (B) The survival of the
three experimental groupswith loss of tumor suppressor in pancreatic
β cells (RIP-rtTA; tet-o-MT; p48-cre; p53lox/lox mice, RIP-rtTA; tet-o-MT;
p48-cre; p16/p19lox/lox mice, RIP-rtTA; tet-o-MT; p48-cre; p53lox/lox;
p16/p19lox/loxmice; all on dox) was statistically shorter than that of the
control RIP-rtTA; tet-o-MT; p48-cremice (on dox).
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survival
Pdx1-tTA; tet-o-PyMT-IRES-Luc; p48-cre; p16/p19lox/lox mice (n =
35, Pdx1-tTA; tet-o-MT; p16/p19lox/lox for short) have significantly
shorter survival (P = .0025) and a slightly higher tumor incidence
than control Pdx1-tTA; tet-o-MT mice (14% vs 5%, P = .0710)
(Table 1, Figure 2A). The predominant tumor that developed was
PanNET, apparent in 3 of 35 mice, and the average tumor burden
was 43 cm3 (range: 33-62 cm3). Only 1 of 35 mice developed mixed
acinar-ductal carcinoma (Table 1). None of the mice developed
metastasis to the liver, suggesting that p16/p19 loss in
PyMT-expressing pancreatic progenitor cells is not sufficient to
promote metastasis.
Concurrent loss of p53 and p16/p19 resembles loss of p53
Combined nullizygosity, Pdx1-tTA; tet-o-PyMT-IRES-Luc;
p48-cre; p53 lox/lox; p16/p19 lox/lox (n = 12, Pdx1-tTA; tet-o-MT;
p53lox/lox; p16/p19lox/lox for short), resulted in significantly shortenedsurvival compared with Pdx1-tTA; tet-o-MTmice (P b .0001) (Table 1,
Figure 2A). The tumor incidence was significantly higher than control
mice (33% vs 5%, P = .0006) (Table 1). Survival was comparable to
Pdx1-tTA; tet-o-MT; p53lox/lox mice but was significantly shorter than
Pdx1-tTA; tet-o-MT; p16/p19lox/lox mice (P = .0449) (Figure 2A). PACC
with liver metastasis occurred in four mice, but there was no PanNET
incidence in this genotype (Table 1). The incidence ofmetastasis is similar
to Pdx1-tTA; tet-o-MT; p53lox/lox but differed significantly from
Pdx1-tTA; tet-o-MT; p16/p19lox/lox (P = .0289). The tumor latency of
Pdx1-tTA; tet-o-MT; p53lox/lox; p16/p19lox/lox closely resembledPdx1-tTA;
tet-o-MT; p53lox/lox (114 vs 119 days). Based on immunohistochemistry,
two tumors were mixed acinar-ductal carcinomas and two were not
determined because of the inability to stain necrotic tissue (Table 1). The
average PACC tumor burdenwas 4447 cm3 (range: 196-6240 cm3). The
tumor measuring 196 cm3 was an acinar nodule in an 84-day-old mouse
in early PACC tumor development. Taken together, the Pdx1-tTA;
tet-o-MT; p53lox/lox; p16/p19lox/lox mice show similar survival, tumor
incidence, phenotype, and metastasis to thePdx1-tTA; tet-o-MT; p53lox/lox
mice, implying that p16/p19 loss has no additive effect to p53 loss.
p16/p19 loss, But Not p53 Loss, Results in Metastatic
PanNETs in β-Cells
In addition to exploring the role of tumor suppressor loss in the
Pdx1-tTA; tet-o-MT mouse model, we determined the contribution
of p53 and p16/p19 loss to PanNET tumorigenesis in
PyMT-expressing β-cells in the RIP7-rtTA; tet-o-MT mouse model.
This model allows for elucidating a role for p53 and p16/p19 in
PanNET tumorigenesis directly from pancreatic β cells.
The rat insulin promoter (RIP) is activated at around day E9.5
[41], and doxycycline is able to cross the placenta and to accumulate
in the milk of lactating females [42] to interact with rtTA for PyMT
induction. Mice with the control RIP7-rtTA; tet-o-MT; p48-cre
genotype (n = 50) developed β-cell hyperplasia and had no PanNET
development. However, PanNETs occurred in 17% of RIP7-rtTA;
tet-o-MT; p48-cre; p53lox/lox mice, 20% of RIP7-rtTA; tet-o-MT;
p48-cre; p16/p19lox/lox mice, and 40% of RIP7-rtTA; tet-o-MT;
p48-cre; p53lox/lox; p16/p19lox/lox mice (Table 1). Liver metastases were
not present in RIP7-rtTA; tet-o-MT; p53lox/lox mice but occurred in 5 of
60 (8%) of RIP7-rtTA; tet-o-MT; p16/p19lox/lox mice and 4 of 30 (13%)
of RIP7-rtTA; tet-o-MT; p53lox/lox; p16/p19lox/lox mice (Table 1). The
absence of metastases from RIP7-rtTA; tet-o-MT; p53lox/lox further
supports that p16/p19 loss is more relevant in PanNET progression than
p53 loss. Figure 3C represents a PanNET and liver metastases that
developed in RIP7-rtTA; tet-o-MT; p16/p19lox/lox. Figure 5, E–H presents
theH&E and immunohistochemical staining of a representative PanNET
from theRIP7-rtTA; tet-o-MT; p16/p19lox/lox genotype. Figure 6C displays
the histology of a typical PanNET liver metastasis.Discussion
We investigate the functions of p53 and p16/p19 tumor suppressor
loss in PACC and PanNET in mouse models. This is the first study,
to our knowledge, that shows a causal role of p53 loss in producing
short-latency, metastatic PACC without neuroendocrine feature. We
found that Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox mice demonstrated
shorter survival, increased tumor incidence, and increased metastasis
as compared with the control Pdx1-tTA; tet-o-MT; p48-cre mice,
emphasizing that p53 plays an important role in PACC progression.
On the other hand, p16/p19 loss is not sufficient to advance PACC
progression. Pdx1-tTA; tet-o-MT; p48-cre; p16/p19lox/lox had no
Figure 3.Macroscopic phenotypic changes of the pancreas and liver. Gross photograph of (A) normal pancreas and liver. (B) PACC tumor
and liver metastases from Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox genotype. (C) PanNET and liver metastases indicated by black arrows in
the RIP7-rtTA; tet-o-MT; p48-cre; p16/p19lox/lox genotype. Pdx1-tTA; tet-o-MT; p48-cre; p16/p19lox/lox mice develop PanNETs but not
metastases. Scale: mm.
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Pdx1-tTA; tet-o-MT; p48-cre mice but did have shortened survival
due to the development of PanNETs. Additionally, there were no
differences in tumor incidence, burden, metastasis, or survival
between concurrent loss of both p53 and p16/p19 and loss of p53
alone in the Pdx1-tTA; tet-o-MT model, suggesting that there is no
additive effect of p16/p19 loss to PACC promoted by p53 loss.
Two elegant studies by Lewis et al. [43] and Morton et al. [44]
used an RCASBP-tva system to deliver PyMT into elastase-tva mice
postnatally. The elastase promoter has been used in transgenic mice
with the intent of expressing genes specifically in the acinar cells of the
pancreas. In this elastase-tva mouse model, RCAS-PyMT induces
only microscopic pancreatic intraepithelial neoplasia in wild-typetumor suppressor background [43]. RCAS-PyMT–induced acinar cell
carcinomas in p53 null background [44] are uniformly positive for
both chymotrypsin (an acinar marker) and synaptophysin
(a neuroendocrine marker). The feature is similar to human mixed
acinar neuroendocrine carcinoma [45]. In contrast, the majority of
acinar tumors in our Pdx1-tTA; tet-o-MT; p48-cre mice or Pdx1-tTA;
tet-o-MT; p48-cre; p53lox/lox mice expressed chymotrypsin but did not
express synaptophysin, and therefore, this PACC tumor type
described here is different from RCAS-PyMT tumors in elastase-tva
mice. We did not see an additive effect of combined p53 and p16/19
deletion for this acinar tumor type in our mouse model, which is
different from the RCAS-PyMT mouse model [44]. Moreover,
RCAS-PyMT–induced acinar cell carcinomas in p16/p19 null
Figure 4. Histologic features of the Pdx1-tTA; tet-o-MT; p48-cremouse model. H&E of (A) normal pancreas, (B) β-cell hyperplasia, and (C)
pure PACC at 10× magnification. Arrows point to normal-sized islets in (A) and β-cell hyperplasia in (B). Bar indicates 200 μm.
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and synaptophysin. However, loss of p16/p19 in Pdx1-tTA;
tet-o-MT; p48-cre; p16/p19lox/lox mice promoted PanNET, which is
negative for chymotrypsin (Figure 5F). Altogether, the differences in
tumor types may reflect cell of origin differences in our tet-inducible
PyMT model and the RCAS-PyMT/elastase-tva model.
In addition, the tumor formation is slower and tumor incidence is
lower in Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox mice than in
RCAS-PyMT infected elastase-tva mice in p53 null background [44].
This could be a consequence of the lowPdx1 expression in acinar cells in
adult pancreas and the timing of PyMT expression during pancreatic
development in Pdx1-tTA; tet-o-MT; p48-cre; p53lox/lox mice.
We did not observe PanNETs in Pdx1-tTA; tet-o-MT; p48-cre;
p53 lox/lox mice. This is likely due to the rapidity of PACC
tumorigenesis, which caused the lethality of the mice. By using
another mouse model, RIP7-rtTA; tet-o-MT, which developed β-cell
hyperplasia, p53 loss resulted in small nodular PanNETs without
metastases, indicating that p53 loss can promote neuroendocrine
tumorigenesis in β-cells but is not a barrier to metastatic potential.
Our study also establishes the causal role of p16/p19 loss in
PanNET tumorigenesis but not in PACC tumorigenesis as evidencedFigure 5. Tumor type determination with immunohistochemistry. P
p48-cre; p53lox/lox mice at 40× magnification stained for (A) H&E, (B)
PanNET tissue from the Pdx1-tTA; tet-o-MT; p48-cre; p16/p19lox/loxmic
synaptophysin (+), and (H) keratin 17/19 (−). Bars indicate 50 μm.by the development of only PanNETs in Pdx1-tTA; tet-o-MT;
p48-cre; p16/p19lox/lox mice. Loss of p16/p19 in Pdx1+ pancreatic
progenitor cells enhanced the tumorigenesis of specifically the β-cell
lineage and not the acinar lineage. Interestingly, p16/p19 loss in the
RIP7-rtTA model promoted liver metastases of PanNET, whereas
its loss in the Pdx1-tTA model did not result in metastasis of
PanNET. The differences could be due to 1) the expression levels of
rtTA and tTA driven by RIP promoter and Pdx1 promoter or 2) the
order of PyMT expression and the p16/p19 loss.
In this study, we demonstrate that with PyMT expression starting from
pancreatic Pdx1+ progenitor cells, p53 loss has a causal role in PACC
tumorigenesis and metastasis, whereas p16/p19 loss promotes long-latency,
nonmetastatic PanNETs.p53 loss andp16/p19 loss donot have cooperative
roles in PACC tumorigenesis. In PyMT-expressing β cells, both tumor
suppressors play critical and cooperative roles in PanNET tumorigenesis.
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